Drug intelligence / Profile preview

butaperazine

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

Butaperazine is a typical antipsychotic drug of the phenothiazine class. It was first approved in 1967 and is believed to have been discontinued in the 1980s[1][2][3]. Butaperazine acts as a neuroleptic and is effective in the management of schizophrenia[4][5][7]. Its mechanism involves antagonism at dopamine receptors, leading to increased striatal and mesolimbic dopamine turnover as shown in animal studies[4][5]. The most common adverse effects are extrapyramidal symptoms and drowsiness[4][5][7].

Brand names: RepoiseTyrylen
Other names: butaperazinebutaperazine maleate

Targets

HRH1 (Histamine H1 Receptor)DRD2 (Dopamine D2 Receptor)DRD1 (Dopamine D1 Receptor)

Beyond the preview

Go deeper on butaperazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on butaperazine.

Explore the full profile